Is Teva the Perfect Stock?

Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everything you could possibly want?

One thing's for sure: If you don't look, you'll never find truly great investments. So let's first take a look at what you'd want to see from a perfect stock, and then decide if Teva Pharmaceutical (Nasdaq: TEVA  ) fits the bill.

The quest for perfection
When you're looking for great stocks, you have to do your due diligence. It's not enough to rely on a single measure, because a stock that looks great based on one factor may turn out to be horrible in other ways. The best stocks excel in many different areas, which all come together to make up a very attractive picture.

Some of the most basic yet important things to look for in a stock are:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales don't mean anything if a company can't turn them into profits. Strong margins ensure a company is able to turn revenue into profit.
  • Balance sheet. Debt-laden companies have banks and bondholders competing with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Companies need to be able to turn their resources into profitable business opportunities. Return on equity helps measure how well a company is finding those opportunities.
  • Valuation. You can't afford to pay too much for even the best companies. Earnings multiples are simple, but using normalized figures gives you a sense of how valuation fits into a longer-term context.
  • Dividends. Investors are demanding tangible proof of profits, and there's nothing more tangible than getting a check every three months. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Teva.

Factor What We Want to See Actual Pass or Fail?
Growth 5-Year Annual Revenue Growth > 15% 23.7% pass
  1-Year Revenue Growth > 12% 21% pass
Margins Gross Margin > 35% 57.2% pass
  Net Margin > 15% 17.1% pass
Balance Sheet Debt to Equity < 50% 36.3% pass
  Current Ratio > 1.3 1.77 pass
Opportunities Return on Equity > 15% 13.7% fail
Valuation Normalized P/E < 20 20.88 fail
Dividends Current Yield > 2% 1.4% fail
  5-Year Dividend Growth > 10% 22.3% pass
       
  Total Score   7 out of 10

Source: Capital IQ, a division of Standard and Poor's. Total score = number of passes.

Teva clocks in with a 7, which is a very good score. The strong showing comes from Teva's impressive business model, which combines two important sources of revenue for the drugmaker.

Teva has posted impressive growth in producing generic versions of drugs initially developed by other companies. In its most recent quarter, Teva grew generic sales by 14%, opening the opportunity to benefit from increasing economies of scale that give it an advantage over smaller competitors Watson Pharmaceutical (NYSE: WPI  ) and Mylan (Nasdaq: MYL  ) .

Moreover, higher production could improve margins beyond their already high levels. While Pfizer (NYSE: PFE  ) faces a potential $12 billion hit when its Lipitor goes off-patent, and Eli Lilly (NYSE: LLY  ) faces a string of patent expirations in the coming years, Teva can capitalize on their drugs' success with timely generics.

Teva has also had some success with proprietary drugs of its own. Its multiple sclerosis drug Copaxone saw sales growth of 21% last quarter, despite heavy competition from other drugmakers. With its powerful one-two punch of generic and branded drugs, Teva is in a prime position to continue to produce strong financial results.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. The Fool owns shares of Teva Pharmaceutical . Pfizer is a Motley Fool Inside Value choice. Try any of our Foolish newsletters today, free for 30 days. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 05, 2010, at 4:56 PM, Ozcutty wrote:

    Teva is truly a world class company, mind you the shares have gone no where lately :(

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1322429, ~/Articles/ArticleHandler.aspx, 12/21/2014 8:40:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement